Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
Samsung Bioepis’ Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck
KENILWORTH, N.J., Dec. 7, 2015 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS™ (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercializeSamsung Bioepis’ RENFLEXIS in Korea as part of Merck’s commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines
0 comentários:
Postar um comentário